tiprankstipranks
Trending News
More News >
Imunon (IMNN)
NASDAQ:IMNN
Advertisement

Imunon (IMNN) AI Stock Analysis

Compare
1,365 Followers

Top Page

IMNN

Imunon

(NASDAQ:IMNN)

Rating:41Neutral
Price Target:
Imunon's financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock's risky profile, with a negative P/E ratio and no dividend yield.
Positive Factors
Partnership Potential
Imunon is optimistic about establishing a beneficial partnership due to the platform's preclinical proof of concept in infectious disease and oncology.
Regulatory Alignment
Imunon has full FDA alignment for its OVATION 3 trial, which is a positive development for advancing their study.
Therapy Efficacy
IMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.
Negative Factors
Capital Requirements
The company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.
Financial Dependency
Imunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.
Trial Enrollment Challenges
The company's focus on enrolling HRD+ patients first could potentially lead to quicker approval due to observed benefits in previous studies.

Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)

Imunon Business Overview & Revenue Model

Company DescriptionImunon, Inc. (IMNN) is a biotechnology company focused on the development and commercialization of innovative therapies that leverage its proprietary platform technologies. The company's primary areas of focus include oncology and infectious diseases, with a core emphasis on developing advanced DNA-based immunotherapies and vaccine solutions. Imunon aims to address unmet medical needs by providing effective and safe treatment options for patients worldwide.
How the Company Makes MoneyImunon generates revenue primarily through the development and commercialization of its proprietary therapeutic and vaccine solutions. The company may engage in licensing agreements, where it partners with other pharmaceutical or biotechnology firms to co-develop or distribute its products, thereby earning licensing fees and royalties. Additionally, Imunon may receive funding from government grants or research collaborations, which contribute to its research and development efforts. By advancing its pipeline of candidates through clinical trials and achieving regulatory approvals, Imunon positions itself to earn revenue from product sales, either directly or through strategic partnerships.

Imunon Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
IMUNON's earnings call highlighted significant progress in its ovarian cancer treatment and the strong start of the Phase III OVATION 3 trial. The company is effectively managing costs and enhancing shareholder value through a stock dividend. However, it faces challenges in the capital markets, requiring ongoing efforts to secure additional funding.
Q2-2025 Updates
Positive Updates
Significant Improvement in Ovarian Cancer Treatment
IMUNON's IMNN-001 therapy showed a median increase in overall survival of 13 months, a 45% improvement, in ovarian cancer patients when combined with standard care chemotherapy.
Phase III OVATION 3 Trial Progress
The OVATION 3 trial has had a strong start, opening sites faster than industry benchmarks, and has already enrolled its first patient. The trial is poised to redefine treatment for advanced ovarian cancer.
Stock Dividend to Enhance Shareholder Value
IMUNON announced a 15% stock dividend to boost shareholder value and confidence in the company's growth potential.
Cost Reduction and Financial Management
Operating expenses declined significantly, with R&D expenses dropping from $2.8 million to $1.2 million, and G&A expenses from $2.2 million to $1.5 million.
Negative Updates
Challenging Capital Markets Environment
IMUNON is facing a difficult capital market environment, impacting its funding strategies and necessitating careful financial management.
Ongoing Need for Additional Funding
While managing costs effectively, IMUNON continues to seek partnerships and additional funding to support its Phase III trial and strategic objectives.
Company Guidance
During the call, IMUNON provided detailed guidance on the progress and future plans for its lead candidate, IMNN-001, a gene-mediated IL-12 therapy for ovarian cancer. The OVATION 2 study showed a median increase in overall survival of 13 months, with a 45% improvement compared to the standard of care alone, and a hazard ratio of 0.69. The use of PARP inhibitors further enhanced outcomes, with median overall survival not yet reached in the IMNN-001 treatment arm after more than five years. The Phase III OVATION 3 trial is underway, with a primary endpoint of overall survival and secondary endpoints including surgical response score, chemotherapy response score, and time to second-line treatment. The trial began with three activated sites and has already randomized and treated its first patient. The company announced a strategy to fund OVATION 3 through partnerships and equity, and recently raised over $3 million through warrant exercises and ATM sales, while also implementing cost-saving measures to extend its cash runway.

Imunon Financial Statement Overview

Summary
Imunon faces significant financial challenges, as indicated by consistently negative revenue, profitability, and cash flow metrics. High leverage and negative returns further exacerbate financial instability. The company needs strategic financial restructuring and improved operational performance to enhance its financial health and investor confidence.
Income Statement
10
Very Negative
Imunon has consistently reported zero or negative revenue over the past years. Gross profit margins are nonexistent, with significant net losses indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, showing a lack of operational efficiency. There is no evidence of revenue growth, suggesting challenges in achieving market penetration or product commercialization.
Balance Sheet
25
Negative
The company exhibits a relatively high debt-to-equity ratio, indicating reliance on debt financing. Return on Equity (ROE) is negative, reflecting ongoing net losses. The equity ratio shows some equity presence but is overshadowed by continuous financial strain. The balance sheet stability is questionable due to high leverage and negative equity returns.
Cash Flow
20
Very Negative
Operating cash flow is consistently negative, reflecting poor cash generation from operations. Free cash flow is also negative, indicating insufficient cash to cover capital expenditures. Despite some positive financing and investing cash flow activities, the company's overall cash flow position is weak, raising concerns about liquidity and future operational funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue727.16K0.000.00500.00K500.00K500.00K
Gross Profit-188.27K-718.12K0.00500.00K500.00K500.00K
EBITDA-15.07M-17.98M-19.88M-31.71M-20.88M-21.30M
Net Income-15.75M-18.62M-19.51M-35.90M-20.77M-21.48M
Balance Sheet
Total Assets8.79M9.72M21.92M43.98M74.05M37.53M
Cash, Cash Equivalents and Short-Term Investments4.73M5.87M15.70M32.75M49.39M17.16M
Total Debt1.19M1.14M1.62M6.27M6.63M6.19M
Total Liabilities6.13M5.47M8.53M14.65M18.25M18.92M
Stockholders Equity2.66M4.24M13.39M29.33M55.80M18.61M
Cash Flow
Free Cash Flow-14.57M-18.88M-19.47M-23.36M-16.54M-15.64M
Operating Cash Flow-14.27M-18.85M-19.02M-23.10M-16.22M-15.62M
Investing Cash Flow-294.77K9.83M11.01M8.28M-30.12M7.92M
Financing Cash Flow13.99M9.06M-3.64M6.72M54.77M17.98M

Imunon Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.93
Price Trends
50DMA
7.69
Negative
100DMA
10.92
Negative
200DMA
11.23
Negative
Market Momentum
MACD
-0.59
Negative
RSI
34.99
Neutral
STOCH
8.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 5.93 is below the 20-day moving average (MA) of 6.57, below the 50-day MA of 7.69, and below the 200-day MA of 11.23, indicating a bearish trend. The MACD of -0.59 indicates Negative momentum. The RSI at 34.99 is Neutral, neither overbought nor oversold. The STOCH value of 8.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.

Imunon Risk Analysis

Imunon disclosed 4 risk factors in its most recent earnings report. Imunon reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Any market activity involving short selling or other market making activities could result in negative impact to the market price for our Common Stock. Q2, 2025
2.
Our Common Stock may be delisted from Nasdaq if we fail to comply with continued listing standards. Q2, 2025
3.
We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without significant dilutive financing transactions, or at all. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates and will not be able to continue as a going concern. Q2, 2025

Imunon Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.33-41.39%2.23%23.26%-2.03%
48
Neutral
$14.68M-137.09%247.62%-7.66%
42
Neutral
$11.28M-102.18%85.26%
41
Neutral
$14.95M-491.97%45.96%
41
Neutral
$159.59M-89.73%-100.00%-221.06%
40
Underperform
$15.39M-110.56%29.97%
34
Underperform
$10.03M-165.56%58.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMNN
Imunon
5.85
-7.85
-57.30%
MEIP
MEI Pharma
4.85
1.75
56.45%
PHIO
Phio Pharmaceuticals
2.12
-0.48
-18.46%
COCP
Cocrystal Pharma
1.50
-0.20
-11.76%
BRTX
BioRestorative Therapies
1.73
0.10
6.13%
INAB
IN8bio
2.21
-11.74
-84.16%

Imunon Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Imunon Appoints Dr. Douglas Faller as CMO
Positive
Feb 10, 2025

On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025